Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique

Clin Infect Dis. 2019 Oct 30;69(10):1809-1811. doi: 10.1093/cid/ciz196.

Abstract

Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.

Keywords: bedaquiline; injectable drugs; multidrug-resistant tuberculosis; short regimen; treatment outcomes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antitubercular Agents / administration & dosage*
  • Diarylquinolines / administration & dosage*
  • Drug Administration Routes
  • Drug Administration Schedule
  • Drug Substitution*
  • Female
  • Humans
  • Injections
  • Kanamycin / adverse effects
  • Kanamycin / therapeutic use
  • Male
  • Middle Aged
  • Mozambique / epidemiology
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / epidemiology

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • Kanamycin
  • bedaquiline